MedTrace Logo

Cardiac REperfusion With Intralipid® at Reperfusion

NCT02807727 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-12-12

No results posted yet for this study

Summary

This study will evaluate the benefit of Intralipid® or placebo administered prior to reperfusion to limit ischemia reperfusion injury as measured by the geometric mean difference of the release of troponin I over 72 hours after coronary artery bypass.

Conditions

  • Reperfusion Injury

Interventions

DRUG

Intralipid 20%

Single intravenous bolus dose of 1.5 ml/kg over 3 minutes

DRUG

Modified Ringers Lactate

Single intravenous bolus dose of 1.5 ml/kg over 3 minutes

Sponsors & Collaborators

  • Nkanyiso Hadebe

    lead OTHER

Principal Investigators

  • Nkanyiso E Hadebe, MBBCh · University of Cape

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02807727 on ClinicalTrials.gov